title: Current and future pharmacologic treatment of sarcopenia.
abstract: Sarcopenia is a complex multifactorial condition that can by treated with multimodal approaches. No pharmacologic agent to prevent or treat sarcopenia has been as efficacious as exercise (mainly resistance training) in combination with nutritional intervention (adequate protein and energy intake). However, performing resistance training sessions and following nutritional advice can be challenging, especially for frail, sarcopenic, elderly patients, and results remain only partial. Therefore, new pharmacologic agents may substantially reduce the functional decline in older people. This article reviews the new pharmacologic agents currently being assessed for treating sarcopenia.
authors.affiliation: Inserm U1027, University of Toulouse III, Avenue Jules Guesdes, France. rolland.y@chu-toulouse.fr
authors.forename: Yves
authors.initials: Y
authors.lastname: Rolland
authors.forename: Graziano
authors.initials: G
authors.lastname: Onder
authors.forename: John E
authors.initials: JE
authors.lastname: Morley
authors.forename: Sophie
authors.initials: S
authors.lastname: Gillette-Guyonet
authors.forename: Gabor
authors.initials: G
authors.lastname: Abellan van Kan
authors.forename: Bruno
authors.initials: B
authors.lastname: Vellas
mesh_terms: D000368:Aged; D000375:Aging; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D004358:Drug Therapy / Q000639:trends*; D016330:Frail Elderly; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D018908:Muscle Weakness / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D055948:Sarcopenia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D006728:Hormones